ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Rapid Multiplex Antimicrobial Resistance Profiling and Bacterial Identification by LAP-MALDI Mass Spectrometry Biotyping.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Rapid and accurate characterization of antimicrobial resistance is essential for effective patient treatment and outcomes. Infection-causing microorganisms often harbour multi-drug resistance, requiring multiple tests for identification. Here, we present a multiplex functional assay using liquid atmospheric pressure (LAP) matrix-assisted laser desorption/ionization (MALDI) as next-generation MALDI biotyping technology, which can accurately determine antibiotic resistance/susceptibility within three hours from <5 µL of bacterial culture, employing a beta-lactam antibiotic panel. Strains with common resistance genes, including OXA-48, KPC-3, and VIM-1, as well as susceptible isolates, are easily and reliably classified. Concurrent with multi-drug testing, the same bacterial sample provides species-identifying lipid and protein profiles (up to 100% classification accuracy) and characterization through tandem mass spectrometry (MS/MS) protein sequencing, facilitated by LAP-MALDI's ability to generate multiply charged protein ions. Detection of multiple antibiotics, their degradation products and lipids/proteins with high mass accuracy, along with the possibility of protein sequencing, offers new diagnostic possibilities for clinical microbiology and antimicrobial stewardship that are less probability-based than conventional MALDI biotyping.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.